Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01935934 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT01935934: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01935934 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01935934, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This phase II trial studies how well cabozantinib s-malate works in treating patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Interventions
- DRUG Cabozantinib S-malate
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-05-08 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01935934
The ClinicalTrials.gov registry entry for NCT01935934 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cabozantinib S-malate is the first listed.
NCT01935934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01935934 about?
NCT01935934 is a clinical study titled "Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer". This phase II trial studies how well cabozantinib s-malate works in treating patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cel...
What is the current status of trial NCT01935934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2013-05-08. Estimated completion is 2024-10-24.
What interventions are being tested in trial NCT01935934?
The interventions under investigation include: Cabozantinib S-malate (DRUG), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01935934?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.